Dalong Zhu

32PUBLICATIONS
63CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)General practicePharmaceutical delivery technologiesTissue engineeringPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Jan 07, 2026
Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial.

Dalong Zhu, Weimin Wang, Guoyu Tong

|Dec 30, 2025
Guidelines on primary healthcare for type 2 diabetes in China, 2025.

Weiping Jia, Dalong Zhu, Lixin Guo

|Dec 17, 2025
Mazdutide versus placebo in Chinese adults with type 2 diabetes.

Dalong Zhu, Jiajun Zhao, Hanqing Cai

|Jul 29, 2025
PU.1 Facilitates Endothelial-to-Mesenchymal Transition in Cardiac Endothelial Cells.

Ran Meng, Bin Huang, Fan Yang

|Jun 05, 2025
Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose-escalation phase 1 study.

Qinghua Wang, Qiaoli Cui, Yulong Xu

|Dec 18, 2024
Effectiveness and Safety of the TRIO Optimal Health Management Program in Patients With Type 2 Diabetes Mellitus Initiating Basal Insulin Therapy: Prospective Observational Real-World Study.

Chenxi Li, Lixin Guo, Lixin Shi

Pageof 6

Frequent Collaborators

6 joint publications

Yan Bi

4 joint publications

Ping Li

3 joint publications

Wenhuan Feng

2 joint publications

Meng-Si Liu